Mostrar el registro sencillo

dc.contributor.authorSánchez Barceló, Emilio José 
dc.contributor.authorMediavilla Aguado, María Dolores 
dc.contributor.authorReiter, Russel J.
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2025-03-19T10:32:32Z
dc.date.available2025-03-19T10:32:32Z
dc.date.issued2011
dc.identifier.issn1687-9759
dc.identifier.issn1687-9740
dc.identifier.otherSAF2007-62762es_ES
dc.identifier.otherPR2009-0240es_ES
dc.identifier.otherPR2009-0244es_ES
dc.identifier.urihttps://hdl.handle.net/10902/36049
dc.description.abstractThis study analyzes the results of clinical trials of treatments with melatonin conducted in children, mostly focused on sleep disorders of different origin. Melatonin is beneficial not only in the treatment of dyssomnias, especially delayed sleep phase syndrome, but also on sleep disorders present in children with attention-deficit hyperactivity, autism spectrum disorders, and, in general, in all sleep disturbances associated with mental, neurologic, or other medical disorders. Sedative properties of melatonin have been used in diagnostic situations requiring sedation or as a premedicant in children undergoing anesthetic procedures. Epilepsy and febrile seizures are also susceptible to treatment with melatonin, alone or associated with conventional antiepileptic drugs. Melatonin has been also used to prevent the progression in some cases of adolescent idiopathic scoliosis. In newborns, and particularly those delivered preterm, melatonin has been used to reduce oxidative stress associated with sepsis, asphyxia, respiratory distress, or surgical stress. Finally, the administration of melatonin, melatonin analogues, or melatonin precursors to the infants through the breast-feeding, or by milk formula adapted for day and night, improves their nocturnal sleep. Side effects of melatonin treatments in children have not been reported. Although the above-described results are promising, specific studies to resolve the problem of dosage, formulations, and length of treatment are necessary.es_ES
dc.description.sponsorshipThis work was supported by a Grant from the Spanish Ministry of Science and Education (SAF2007-62762). The stay of E. J. Sánchez-Barcel ´o and D. Mediavilla in the University of Texas has been subsidized by the Grants PR2009-0240 and PR2009-0244 (Spanish Ministry of Education).es_ES
dc.format.extent11 p.es_ES
dc.language.isoenges_ES
dc.publisherJohn Wiley & Sonses_ES
dc.rightsAttribution 4.0 Internationales_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceInternational Journal of Pediatrics, 2011, 1, 892624es_ES
dc.titleClinical uses of melatonin in pediatricses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.1155/2011/892624es_ES
dc.rights.accessRightsopenAccesses_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/MEC//SAF2007-62762/ES/MELATONINA:I. INTERACCION CON RECEPTORES ESTROGENICOS NUCLEARES Y DE MEMBRANA; II. PAPEL EN LA HIPERSENSIBILIDAD ADAPTATIVA A ESTROGENOS; III. INTERACCION CON XENOESTROGENOS/es_ES
dc.identifier.DOI10.1155/2011/892624
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

Attribution 4.0 InternationalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International